Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Oman International Hospital in Muscat, Oman

The Idealmed Global Healthcare Services (Idealmed GHS),  part of the european  health group IGHS, based in Coimbra, Portugal, starts the comissioning of the impressive “Oman International Hospital”.

Having participated in projects in Asia, Europe, Africa and in the Midle East, the extraordinary recently launched “Oman International Hospital” (OIH), is the perfect example of the Idealmed GHS capabilities. The OIH was fully conceived, designed and equipped by Idealmed GHS, that will now operate the Hospital in accordance with the most exigent international standards of quality.

With matchless conditions, the “Oman International Hospital” is already considered a landmark in Oman and assumes the ambition to lead the private health sector in the country and in the region, by providing the most advanced diagnostic and treatment solutions to all its users.

As per vision of the Idealmed GHS, the OIH also hosts a “Med Academy”, fully sustained by Siemens, that will ensure the continous training of all its Human Resources and the implementation of international programmes that promotes the sharing of competences and experiences.

Idealmed GHS integrates the international know-how of the most distinguished organizations, from Universities to R&D Institutions, leading multinacional companies, and other renowned hospital groups worldwide, with the single aim to conceive, develop and operate unique health projects, allowing its partners to have a single entity fully responsible for its implementation and governance.

Idealmed GHS assumes its international linkage with companies like Siemens, IBM, among many others, and the relation with the Academic world, in particular with the University of Coimbra, one of the oldest and most prestigious International Universities, as its key pillars of success.

“Knowing that in a modern world knowledge has no boundaries, at Idealmed GHS we merge the experience of all our partners, crafting healthcare projects and tailoring services to each individual.

“In all our facilities, we integrate culture with science, safety with confort, and aesthetics with functionality. Using the most innovative layouts and engeneering concepts and leading-edge eqquipment solutions, we combine techonlogical sophostication with the know-how of the most skilled and trained Human Resources.

“At Idealmed GHS we assume a disruptive vision for hospitals, leading innovative projects and  maximizing their sustainability and profitability, enhancing the confort and well-being of its users and surpassing their superlative expectations,” stated Dr. José Alexandre Cunha, Chairman Of Idealmed GHS.

“Crafting healthcare projects, tailoring services to each individual.”

“Toghether we do it better.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy